323 related articles for article (PubMed ID: 19900449)
1. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
[TBL] [Abstract][Full Text] [Related]
2. Risks of less common cancers in proven mutation carriers with lynch syndrome.
Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
[TBL] [Abstract][Full Text] [Related]
3. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
4. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
[TBL] [Abstract][Full Text] [Related]
5. Evidence for breast cancer as an integral part of Lynch syndrome.
Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
[TBL] [Abstract][Full Text] [Related]
6. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis.
Jenkins MA; Dowty JG; Ait Ouakrim D; Mathews JD; Hopper JL; Drouet Y; Lasset C; Bonadona V; Win AK
J Clin Oncol; 2015 Feb; 33(4):326-31. PubMed ID: 25534380
[TBL] [Abstract][Full Text] [Related]
7. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
[TBL] [Abstract][Full Text] [Related]
8. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
[TBL] [Abstract][Full Text] [Related]
9. Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
Balmaña J; Stockwell DH; Steyerberg EW; Stoffel EM; Deffenbaugh AM; Reid JE; Ward B; Scholl T; Hendrickson B; Tazelaar J; Burbidge LA; Syngal S
JAMA; 2006 Sep; 296(12):1469-78. PubMed ID: 17003395
[TBL] [Abstract][Full Text] [Related]
10. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
[TBL] [Abstract][Full Text] [Related]
11. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
[TBL] [Abstract][Full Text] [Related]
12. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study.
Harkness EF; Barrow E; Newton K; Green K; Clancy T; Lalloo F; Hill J; Evans DG
J Med Genet; 2015 Aug; 52(8):553-6. PubMed ID: 26101330
[TBL] [Abstract][Full Text] [Related]
13. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
Boilesen AE; Bisgaard ML; Bernstein I
Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
Kastrinos F; Ojha RP; Leenen C; Alvero C; Mercado RC; Balmaña J; Valenzuela I; Balaguer F; Green R; Lindor NM; Thibodeau SN; Newcomb P; Win AK; Jenkins M; Buchanan DD; Bertario L; Sala P; Hampel H; Syngal S; Steyerberg EW;
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582061
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
[TBL] [Abstract][Full Text] [Related]
16. Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1.
Lin-Hurtubise KM; Yheulon CG; Gagliano RA; Lynch HT
J Surg Oncol; 2013 Dec; 108(7):433-7. PubMed ID: 24122742
[TBL] [Abstract][Full Text] [Related]
17. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
[TBL] [Abstract][Full Text] [Related]
18. Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.
Bozzao C; Lastella P; Ponz de Leon M; Pedroni M; Di Gregorio C; D'Ovidio FD; Resta N; Prete F; Guanti G; Stella A
Cancer; 2011 Sep; 117(18):4325-35. PubMed ID: 21387278
[TBL] [Abstract][Full Text] [Related]
19. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
Järvinen HJ; Renkonen-Sinisalo L; Aktán-Collán K; Peltomäki P; Aaltonen LA; Mecklin JP
J Clin Oncol; 2009 Oct; 27(28):4793-7. PubMed ID: 19720893
[TBL] [Abstract][Full Text] [Related]
20. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
